Sofosbuvir/velpatasvir for 12 weeks results in high SVR12 rates with a favorable safety profile in asian patients: an integrated subgroup analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies
- Publication date
- 1 January 2017
- Publisher
- 'United States Sports Academy'